Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Avoro Capital Advisors LLC

Avoro Capital Advisors LLC trimmed its stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 7.9% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,888,437 shares of the company’s stock after selling 333,785 shares during the period. Syndax Pharmaceuticals comprises about 1.1% of Avoro Capital Advisors LLC’s holdings, making the stock its 23rd biggest position. Avoro Capital Advisors LLC owned about 4.57% of Syndax Pharmaceuticals worth $79,830,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Kynam Capital Management LP boosted its position in shares of Syndax Pharmaceuticals by 41.5% in the 4th quarter. Kynam Capital Management LP now owns 5,660,000 shares of the company’s stock worth $122,313,000 after buying an additional 1,660,000 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Syndax Pharmaceuticals by 13.6% during the first quarter. Vanguard Group Inc. now owns 4,926,984 shares of the company’s stock valued at $117,262,000 after acquiring an additional 591,631 shares during the last quarter. Avidity Partners Management LP raised its stake in Syndax Pharmaceuticals by 40.0% in the 4th quarter. Avidity Partners Management LP now owns 3,950,000 shares of the company’s stock valued at $85,360,000 after purchasing an additional 1,129,000 shares during the last quarter. Point72 Asset Management L.P. lifted its holdings in Syndax Pharmaceuticals by 35.3% in the 4th quarter. Point72 Asset Management L.P. now owns 2,834,499 shares of the company’s stock valued at $61,254,000 after purchasing an additional 740,298 shares in the last quarter. Finally, Sofinnova Investments Inc. grew its holdings in shares of Syndax Pharmaceuticals by 33.9% during the second quarter. Sofinnova Investments Inc. now owns 2,153,669 shares of the company’s stock worth $44,215,000 after buying an additional 545,129 shares in the last quarter.

Analysts Set New Price Targets

A number of brokerages recently issued reports on SNDX. HC Wainwright raised their target price on shares of Syndax Pharmaceuticals from $41.00 to $45.00 and gave the stock a “buy” rating in a research report on Thursday, August 15th. Barclays upped their target price on Syndax Pharmaceuticals from $32.00 to $33.00 and gave the company an “overweight” rating in a research note on Thursday, August 15th. Citigroup increased their target price on Syndax Pharmaceuticals from $30.00 to $34.00 and gave the stock a “buy” rating in a research report on Friday, August 16th. JPMorgan Chase & Co. lowered their price target on Syndax Pharmaceuticals from $34.00 to $33.00 and set an “overweight” rating for the company in a report on Tuesday, August 6th. Finally, Bank of America upped their price objective on shares of Syndax Pharmaceuticals from $30.00 to $31.00 and gave the company a “buy” rating in a research note on Thursday, August 15th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, Syndax Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $35.33.

Syndax Pharmaceuticals Stock Down 1.9 %

Syndax Pharmaceuticals stock opened at $18.27 on Monday. The firm has a market capitalization of $1.55 billion, a P/E ratio of -5.67 and a beta of 0.91. The firm has a fifty day moving average of $20.71 and a 200-day moving average of $21.15. Syndax Pharmaceuticals, Inc. has a 52-week low of $11.22 and a 52-week high of $25.34.

Syndax Pharmaceuticals (NASDAQ:SNDX) last released its quarterly earnings data on Thursday, August 1st. The company reported ($0.80) EPS for the quarter, beating the consensus estimate of ($0.91) by $0.11. The company had revenue of $3.50 million during the quarter. During the same quarter in the previous year, the business earned ($0.64) earnings per share. Syndax Pharmaceuticals’s revenue for the quarter was up 3499999990.0% compared to the same quarter last year. On average, research analysts expect that Syndax Pharmaceuticals, Inc. will post -3.66 EPS for the current fiscal year.

Syndax Pharmaceuticals Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).